Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Bristol Expects FDA Advisory Committee Review Of Muraglitazar

Nov 17 2004

• By Lee Kalowski

Related Content

FDA Delays PPAR Development Pending Carcinogenicity Tests, Ligand Says

Jul 09 2004

Merck Gets Second Chance On Dual PPAR: Will Co-Develop Bristol's Muraglitazar

Apr 28 2004

Additional Topics

BioPharmaceutical

More from Archive

More from Pink Sheet

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window